
Retractable Technologies RVP
$ 0.69
-0.01%
Annual report 2025
added 03-27-2026
Retractable Technologies Interest Expense 2011-2026 | RVP
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Retractable Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 227 K | 260 K | 167 K | 177 K | 211 K | 213 K | 220 K | 223 K | 231 K | 231 K | 240 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 260 K | 167 K | 218 K |
Quarterly Interest Expense Retractable Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 33.5 K | - | 36.1 K | 37.5 K | 43.6 K | - | 40.3 K | 38.4 K | 47.1 K | - | 52.9 K | 54.7 K | 65.1 K | - | 36.1 K | 36 K | 33.8 K | 36 K | 40.7 K | 43.5 K | 45.9 K | 41 K | 42 K | 44 K | 50 K | - | 53 K | 58 K | 48.1 K | - | 52 K | 56.7 K | 49.6 K | - | 58.3 K | 53.1 K | 53.8 K | - | 55.2 K | 56 K | 57.2 K | - | 59.5 K | 60.6 K | 52.1 K | - | 69 K | 70.3 K | 72.1 K | - | 62.5 K | 65.5 K | 56.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 72.1 K | 33.5 K | 50.4 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
-16.4 M | $ 60.84 | 0.76 % | $ 12.1 B | ||
|
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | ||
|
ICU Medical
ICUI
|
93.3 M | $ 122.4 | -0.48 % | $ 3.02 B | ||
|
iRhythm Technologies
IRTC
|
5.44 M | $ 114.08 | -0.07 % | $ 3.65 B | ||
|
Alcon
ALC
|
204 M | $ 64.65 | 1.02 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
9.91 K | $ 3.91 | -1.75 % | $ 181 M | ||
|
LeMaitre Vascular
LMAT
|
5.18 M | $ 99.4 | -0.1 % | $ 2.25 B | ||
|
Masimo Corporation
MASI
|
300 K | $ 178.41 | 0.03 % | $ 9.51 B | ||
|
Ekso Bionics Holdings
EKSO
|
-26 K | - | - | $ 28.6 M | ||
|
Envista Holdings Corporation
NVST
|
-2.3 M | $ 23.9 | 0.21 % | $ 4.02 B | ||
|
electroCore
ECOR
|
14.9 K | $ 6.3 | -2.02 % | $ 53.4 K | ||
|
Haemonetics Corporation
HAE
|
-9.75 M | $ 57.35 | 0.46 % | $ 2.89 B | ||
|
Isoray
ISR
|
84 K | - | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
13.6 M | $ 143.0 | 0.6 % | $ 6.93 B | ||
|
STAAR Surgical Company
STAA
|
2.25 M | $ 31.91 | -0.31 % | $ 1.58 B | ||
|
STERIS plc
STE
|
8.4 M | $ 216.15 | 0.08 % | $ 21.3 B | ||
|
Teleflex Incorporated
TFX
|
85.1 M | $ 130.56 | 0.21 % | $ 5.83 B | ||
|
InfuSystem Holdings
INFU
|
2 K | $ 8.43 | -2.37 % | $ 174 M | ||
|
Microbot Medical
MBOT
|
-5 K | $ 1.92 | 3.69 % | $ 87.9 M | ||
|
Milestone Scientific
MLSS
|
60.3 K | $ 0.34 | -1.02 % | $ 27.9 M | ||
|
Merit Medical Systems
MMSI
|
-2.39 M | $ 62.37 | -0.3 % | $ 3.69 B | ||
|
Utah Medical Products
UTMD
|
-120 K | $ 63.24 | -0.72 % | $ 205 M | ||
|
West Pharmaceutical Services
WST
|
-1 M | $ 301.21 | 0.34 % | $ 21.8 B | ||
|
Pulse Biosciences
PLSE
|
-52 K | $ 25.45 | -6.09 % | $ 1.72 B | ||
|
DENTSPLY SIRONA
XRAY
|
24 M | $ 10.1 | -3.03 % | $ 2.01 B | ||
|
Pro-Dex
PDEX
|
533 K | $ 57.73 | -1.57 % | $ 190 M | ||
|
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
1.82 M | $ 20.76 | -1.42 % | $ 991 M | ||
|
Stereotaxis
STXS
|
2 K | $ 1.89 | -2.83 % | $ 172 M | ||
|
Baxter International
BAX
|
290 M | $ 17.62 | -0.96 % | $ 9.04 B | ||
|
ResMed
RMD
|
3.2 M | $ 204.91 | 1.21 % | $ 29.9 B | ||
|
AtriCure
ATRC
|
683 K | $ 28.69 | 1.92 % | $ 1.37 B | ||
|
Harvard Bioscience
HBIO
|
-2.66 M | $ 5.34 | -3.26 % | $ 237 M | ||
|
AngioDynamics
ANGO
|
4.94 M | $ 10.98 | -0.45 % | $ 449 M | ||
|
Becton, Dickinson and Company
BDX
|
613 M | $ 143.99 | -0.33 % | $ 41.4 B | ||
|
Nephros
NEPH
|
-78 K | $ 3.2 | -4.23 % | $ 34 M | ||
|
OraSure Technologies
OSUR
|
229 K | $ 3.04 | 3.05 % | $ 223 M | ||
|
Repligen Corporation
RGEN
|
2.82 M | $ 106.8 | 3.31 % | $ 6.01 M |